Effects of ONO-6950, a Novel Dual Cysteinyl Leukotriene 1 and 2 Receptor Antagonist, in a Rat Model of Pulmonary Arterial Hypertension
Abstract
The effects of ONO-6950, a novel dual antagonist of cysteinyl leukotriene 1 (CysLT1) and 2 (CysLT2) receptors, were examined in a monocrotaline-induced rat model of pulmonary arterial hypertension (PAH). The effects were compared with those of montelukast (selective CysLT1 receptor antagonist), bosentan (endothelin receptor antagonist), and imatinib (tyrosine kinase inhibitor). In the rat PAH model, ONO-6950 (10, 30, or 100 mg/kg, p.o.) and bosentan (50 mg/kg, p.o.) significantly ameliorated right ventricular hypertrophy and elevation of right ventricular pressure, both indices of PAH, whereas montelukast showed only limited efficacy. Histopathological evaluation revealed that ONO-6950 showed a weak trend toward improvement in pulmonary vascular remodeling and inflammatory cell infiltration in lung tissue. Furthermore, ONO-6950 and imatinib similarly prolonged survival in the rat PAH model. These results demonstrate that ONO-6950 is an orally active dual CysLT1/CysLT2 receptor antagonist that may provide a novel therapeutic option for PAH.
Related
- Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials
- Natriuretic Peptide Receptor-C (NPR3) in Pulmonary Hypertension Associated with Chronic Lung Disease: A PRISMA-ScR Scoping Review of Diagnostic, Prognostic, Mechanistic, and Therapeutic Evidence
- Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF
- Adiponectin and Pulmonary Hypertension Risk: Mendelian Randomization and Receptor‐Side Genetic Evidence
- Covalent targeting of IP receptor and PTEN mediates pyrrolizidine alkaloid-induced pulmonary hypertension
BibTeX
@article{kamiya2026effects,
title = {{Effects of ONO-6950, a Novel Dual Cysteinyl Leukotriene 1 and 2 Receptor Antagonist, in a Rat Model of Pulmonary Arterial Hypertension}},
author = {Akihiro Kamiya and Masabumi Minami},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = oct,
doi = {10.1248/bpb.b26-00345},
url = {https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00345/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Effects of ONO-6950, a Novel Dual Cysteinyl Leukotriene 1 and 2 Receptor Antagonist, in a Rat Model of Pulmonary Arterial Hypertension
AU - Akihiro Kamiya
AU - Masabumi Minami
PY - 2026
DA - 2026/10/10
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00345
UR - https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00345/_article
AB - The effects of ONO-6950, a novel dual antagonist of cysteinyl leukotriene 1 (CysLT1) and 2 (CysLT2) receptors, were examined in a monocrotaline-induced rat model of pulmonary arterial hypertension (PAH). The effects were compared with those of montelukast (selective CysLT1 receptor antagonist), bosentan (endothelin receptor antagonist), and imatinib (tyrosine kinase inhibitor). In the rat PAH model, ONO-6950 (10, 30, or 100 mg/kg, p.o.) and bosentan (50 mg/kg, p.o.) significantly ameliorated right ventricular hypertrophy and elevation of right ventricular pressure, both indices of PAH, whereas montelukast showed only limited efficacy. Histopathological evaluation revealed that ONO-6950 showed a weak trend toward improvement in pulmonary vascular remodeling and inflammatory cell infiltration in lung tissue. Furthermore, ONO-6950 and imatinib similarly prolonged survival in the rat PAH model. These results demonstrate that ONO-6950 is an orally active dual CysLT1/CysLT2 receptor antagonist that may provide a novel therapeutic option for PAH.
SN - 1347-5215
SN - 0918-6158
ER -